{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T15:59:38Z","timestamp":1791820778483,"version":"4.3.4"},"reference-count":207,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,3]],"date-time":"2022-10-03T00:00:00Z","timestamp":1664755200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000065","name":"NINDS","doi-asserted-by":"publisher","award":["F30HD103447"],"award-info":[{"award-number":["F30HD103447"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"NINDS","doi-asserted-by":"publisher","award":["R01 NS065808"],"award-info":[{"award-number":["R01 NS065808"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"NINDS","doi-asserted-by":"publisher","award":["RO1NS100779"],"award-info":[{"award-number":["RO1NS100779"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009429","name":"Israel National Road Safety Authority","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009633","name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development","doi-asserted-by":"publisher","award":["R00HD096115"],"award-info":[{"award-number":["R00HD096115"]}],"id":[{"id":"10.13039\/100009633","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014177","name":"Legacy of Angels Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014177","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008731","name":"Association Europ\u00e9enne contre les Leucodystrophies","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008731","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.ymthe.2022.09.017","type":"journal-article","created":{"date-parts":[[2022,10,3]],"date-time":"2022-10-03T22:38:43Z","timestamp":1664836723000},"page":"7-23","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases"],"prefix":"10.1016","volume":"31","author":[{"given":"Gregory","family":"Heller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison M.","family":"Bradbury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark S.","family":"Sands","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1664-6634","authenticated-orcid":false,"given":"Ernesto R.","family":"Bongarzone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2022.09.017_bib1","doi-asserted-by":"crossref","first-page":"559804","DOI":"10.3389\/fmolb.2020.559804","article-title":"CNS-targeting therapies for lysosomal storage diseases: current advances and challenges","volume":"7","author":"Edelmann","year":"2020","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.ymthe.2022.09.017_bib2","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1093\/brain\/39.1-2.74","article-title":"Infantile form of diffuse brain-sclerosis","volume":"39","author":"Krabbe","year":"1916","journal-title":"Brain"},{"key":"10.1016\/j.ymthe.2022.09.017_bib3","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1136\/jnnp.26.3.195","article-title":"Diagnosis of Krabbe's infantile leucodystrophy","volume":"26","author":"Hagberg","year":"1963","journal-title":"J.\u00a0Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.ymthe.2022.09.017_bib4","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1177\/08830738211027717","article-title":"Hospitalization burden and incidence of krabbe disease","volume":"37","author":"Ghabash","year":"2022","journal-title":"J.\u00a0Child Neurol."},{"key":"10.1016\/j.ymthe.2022.09.017_bib5","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/gim.2015.211","article-title":"Newborn screening for Krabbe disease in New York State: the first eight years' experience","volume":"18","author":"Orsini","year":"2016","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymthe.2022.09.017_bib6","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1007\/BF02185759","article-title":"Two different mutations are responsible for Krabbe disease in the Druze and Moslem Arab populations in Israel","volume":"97","author":"Rafi","year":"1996","journal-title":"Hum. Genet."},{"key":"10.1016\/j.ymthe.2022.09.017_bib7","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1073\/pnas.66.2.302","article-title":"Globoid cell leucodystrophy (Krabbe's disease): deficiency of galactocerebroside beta-galactosidase","volume":"66","author":"Suzuki","year":"1970","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2022.09.017_bib8","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/0014-4886(70)90037-3","article-title":"Studies in globoid leukodystrophy: enzymatic and lipid findings in the canine form","volume":"29","author":"Suzuki","year":"1970","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.ymthe.2022.09.017_bib9","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S0022-2275(20)42957-8","article-title":"Globoid cell leukodystrophy (Krabbe's disease): isolation of myelin with normal glycolipid composition","volume":"11","author":"Eto","year":"1970","journal-title":"J.\u00a0Lipid Res."},{"key":"10.1016\/j.ymthe.2022.09.017_bib10","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/00005072-196504000-00008","article-title":"Studies in globoid (krabbe) leukodystrophy. 3. Significance of experimentally-produced globoid-like elements in rat white matter and spleen","volume":"24","author":"Austin","year":"1965","journal-title":"J.\u00a0Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.ymthe.2022.09.017_bib11","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0022-2275(20)39839-4","article-title":"Krabbe disease: a galactosylsphingosine (psychosine) lipidosis","volume":"21","author":"Svennerholm","year":"1980","journal-title":"J.\u00a0Lipid Res."},{"key":"10.1016\/j.ymthe.2022.09.017_bib12","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0021-9258(18)69582-1","article-title":"The enzymatic synthesis of psychosine","volume":"235","author":"Cleland","year":"1960","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ymthe.2022.09.017_bib13","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/0006-291X(72)90381-6","article-title":"Globoid cell leukodystrophy: additional deficiency of psychosine galactosidase","volume":"48","author":"Miyatake","year":"1972","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ymthe.2022.09.017_bib14","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1126\/science.6719111","article-title":"Progressive accumulation of toxic metabolite in a genetic leukodystrophy","volume":"224","author":"Igisu","year":"1984","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2022.09.017_bib15","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0006-291X(87)80472-2","article-title":"Globoid cell leukodystrophy is a generalized galactosylsphingosine (psychosine) storage disease","volume":"144","author":"Kobayashi","year":"1987","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ymthe.2022.09.017_bib16","doi-asserted-by":"crossref","first-page":"6068","DOI":"10.1523\/JNEUROSCI.5597-08.2009","article-title":"Psychosine accumulates in membrane microdomains in the brain of krabbe patients, disrupting the raft architecture","volume":"29","author":"White","year":"2009","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.ymthe.2022.09.017_bib17","doi-asserted-by":"crossref","first-page":"3303","DOI":"10.1194\/jlr.M039610","article-title":"Psychosine, the cytotoxic sphingolipid that accumulates in globoid cell leukodystrophy, alters membrane architecture","volume":"54","author":"Hawkins-Salsbury","year":"2013","journal-title":"J.\u00a0Lipid Res."},{"key":"10.1016\/j.ymthe.2022.09.017_bib18","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1097\/00005072-199906000-00009","article-title":"An apoptotic depletion of oligodendrocytes in the twitcher, a murine model of globoid cell leukodystrophy","volume":"58","author":"Taniike","year":"1999","journal-title":"J.\u00a0Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.ymthe.2022.09.017_bib19","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1023\/A:1010991420942","article-title":"Psychosine is as potent an inducer of cell death as C6-ceramide in cultured fibroblasts and in MOCH-1 cells","volume":"26","author":"Tohyama","year":"2001","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.ymthe.2022.09.017_bib20","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0304-3940(02)00655-9","article-title":"Apoptotic positive cells in Krabbe brain and induction of apoptosis in rat C6 glial cells by psychosine","volume":"330","author":"Jatana","year":"2002","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.ymthe.2022.09.017_bib21","doi-asserted-by":"crossref","first-page":"896314","DOI":"10.3389\/fnmol.2022.896314","article-title":"CRISPR-Cas9 knock-in of T513M and G41S mutations in the murine beta-galactosyl-ceramidase gene Re-capitulates early-onset and adult-onset forms of krabbe disease","volume":"15","author":"Rebiai","year":"2022","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.ymthe.2022.09.017_bib22","doi-asserted-by":"crossref","first-page":"20097","DOI":"10.1073\/pnas.1912108116","article-title":"Genetic ablation of acid ceramidase in Krabbe disease confirms the psychosine hypothesis and identifies a new therapeutic target","volume":"116","author":"Li","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2022.09.017_bib23","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/j.1471-4159.1974.tb06882.x","article-title":"The biosynthesis and concentration of galactosyl diglyceride in glial and neuronal enriched fractions of actively myelinating rat brain","volume":"22","author":"Deshmukh","year":"1974","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.ymthe.2022.09.017_bib24","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1093\/brain\/47.4.489","article-title":"The encephalitis periaxialis of Schilder: a clinical and pathological study with an account of two cases, one of which was diagnosed during life","volume":"47","author":"Collier","year":"1924","journal-title":"Brain"},{"key":"10.1016\/j.ymthe.2022.09.017_bib25","doi-asserted-by":"crossref","first-page":"e0178103","DOI":"10.1371\/journal.pone.0178103","article-title":"Psychosine enhances the shedding of membrane microvesicles: implications in demyelination in Krabbe's disease","volume":"12","author":"D'Auria","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.ymthe.2022.09.017_bib26","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1523\/JNEUROSCI.2431-14.2015","article-title":"Mechanism of neuromuscular dysfunction in Krabbe disease","volume":"35","author":"Cantuti-Castelvetri","year":"2015","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.ymthe.2022.09.017_bib27","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s00401-011-0814-2","article-title":"Axonopathy is a compounding factor in the pathogenesis of Krabbe disease","volume":"122","author":"Castelvetri","year":"2011","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.ymthe.2022.09.017_bib28","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.nbd.2012.01.013","article-title":"Psychosine induces the dephosphorylation of neurofilaments by deregulation of PP1 and PP2A phosphatases","volume":"46","author":"Cantuti-Castelvetri","year":"2012","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.ymthe.2022.09.017_bib29","doi-asserted-by":"crossref","first-page":"10048","DOI":"10.1523\/JNEUROSCI.0217-13.2013","article-title":"The sphingolipid psychosine inhibits fast axonal transport in Krabbe disease by activation of GSK3beta and deregulation of molecular motors","volume":"33","author":"Cantuti Castelvetri","year":"2013","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.ymthe.2022.09.017_bib30","doi-asserted-by":"crossref","first-page":"dmm036590","DOI":"10.1242\/dmm.036590","article-title":"Inhibition of the IGF-1-PI3K-Akt-mTORC2 pathway in lipid rafts increases neuronal vulnerability in a genetic lysosomal glycosphingolipidosis","volume":"12","author":"Sural-Fehr","year":"2019","journal-title":"Dis. Model. Mech."},{"key":"10.1016\/j.ymthe.2022.09.017_bib31","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s13023-018-0872-9","article-title":"A prospective natural history study of Krabbe disease in a patient cohort with onset between 6\u00a0months and 3 years of life","volume":"13","author":"Bascou","year":"2018","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymthe.2022.09.017_bib32","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1002\/jnr.23743","article-title":"Krabbe disease: one Hundred years from the bedside to the bench to the bedside","volume":"94","author":"Wenger","year":"2016","journal-title":"J.\u00a0Neurosci. Res."},{"key":"10.1016\/j.ymthe.2022.09.017_bib33","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1007\/s10545-012-9560-4","article-title":"Krabbe disease in adults: phenotypic and genotypic update from a series of 11 cases and a review","volume":"36","author":"Debs","year":"2013","journal-title":"J.\u00a0Inherit. Metab. Dis."},{"key":"10.1016\/j.ymthe.2022.09.017_bib34","first-page":"37","article-title":"Krabbe disease locus mapped to chromosome 14 by genetic linkage","volume":"47","author":"Zlotogora","year":"1990","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ymthe.2022.09.017_bib35","first-page":"1250","article-title":"Localization of the Krabbe disease gene (GALC) on chromosome 14 by multipoint linkage analysis","volume":"53","author":"Oehlmann","year":"1993","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ymthe.2022.09.017_bib36","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1093\/hmg\/2.11.1841","article-title":"Cloning and expression of cDNA encoding human galactocerebrosidase, the enzyme deficient in globoid cell leukodystrophy","volume":"2","author":"Chen","year":"1993","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymthe.2022.09.017_bib37","unstructured":"Wenger, D.A., Escolar, M.L., Luzi, P., Rafi, M.A. Krabbe Disease (Globoid Cell Leukodystrophy). In The Online Metabolic and Molecular Bases of Inherited Disease. Chapter 8, 2013. McGraw Hill Ed. N.Y."},{"key":"10.1016\/j.ymthe.2022.09.017_bib38","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.gene.2014.09.046","article-title":"History, genetic, and recent advances on Krabbe disease","volume":"555","author":"Graziano","year":"2015","journal-title":"Gene"},{"key":"10.1016\/j.ymthe.2022.09.017_bib39","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1023\/A:1005315311165","article-title":"Prevalent mutations in the GALC gene of patients with Krabbe disease of Dutch and other European origin","volume":"20","author":"Kleijer","year":"1997","journal-title":"J.\u00a0Inherit. Metab. Dis."},{"key":"10.1016\/j.ymthe.2022.09.017_bib40","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/(SICI)1098-1004(1997)10:4<268::AID-HUMU2>3.0.CO;2-D","article-title":"Molecular genetics of Krabbe disease (globoid cell leukodystrophy): diagnostic and clinical implications","volume":"10","author":"Wenger","year":"1997","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.ymthe.2022.09.017_bib41","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1093\/hmg\/4.8.1285","article-title":"A large deletion together with a point mutation in the GALC gene is a common mutant allele in patients with infantile Krabbe disease","volume":"4","author":"Rafi","year":"1995","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymthe.2022.09.017_bib42","first-page":"1233","article-title":"Molecular heterogeneity of late-onset forms of globoid-cell leukodystrophy","volume":"59","author":"De Gasperi","year":"1996","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ymthe.2022.09.017_bib43","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/(SICI)1098-1004(1999)14:3<256::AID-HUMU9>3.0.CO;2-6","article-title":"Molecular basis of late-life globoid cell leukodystrophy","volume":"14","author":"De Gasperi","year":"1999","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.ymthe.2022.09.017_bib44","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/ana.410400119","article-title":"Multiple mutations in the GALC gene in a patient with adult-onset Krabbe disease","volume":"40","author":"Luzi","year":"1996","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ymthe.2022.09.017_bib45","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/0006-8993(80)90159-6","article-title":"The Twitcher mouse: an enzymatically authentic model of human globoid cell leukodystrophy (Krabbe disease)","volume":"202","author":"Kobayashi","year":"1980","journal-title":"Brain Res."},{"key":"10.1016\/j.ymthe.2022.09.017_bib46","first-page":"165","article-title":"Globoid cell leukodystrophy (Krabbe type) in the dog","volume":"149","author":"Fletcher","year":"1966","journal-title":"J.\u00a0Am. Vet. Med. Assoc."},{"key":"10.1016\/j.ymthe.2022.09.017_bib47","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1006\/geno.1997.4744","article-title":"Characterization of the rhesus monkey galactocerebrosidase (GALC) cDNA and gene and identification of the mutation causing globoid cell leukodystrophy (Krabbe disease) in this primate","volume":"42","author":"Luzi","year":"1997","journal-title":"Genomics"},{"key":"10.1016\/j.ymthe.2022.09.017_bib48","first-page":"476","article-title":"Genetic galactocerebrosidase deficiency (globoid cell leukodystrophy, Krabbe disease) in rhesus monkeys (Macaca mulatta)","volume":"48","author":"Baskin","year":"1998","journal-title":"Lab. Anim. Sci."},{"key":"10.1016\/j.ymthe.2022.09.017_bib49","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1126\/science.6382609","article-title":"Prolonged survival and remyelination after hematopoietic cell transplantation in the twitcher mouse","volume":"225","author":"Yeager","year":"1984","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2022.09.017_bib50","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/(SICI)1097-4547(20000415)60:2<231::AID-JNR12>3.0.CO;2-E","article-title":"L-cycloserine slows the clinical and pathological course in mice with globoid cell leukodystrophy (twitcher mice)","volume":"60","author":"LeVine","year":"2000","journal-title":"J.\u00a0Neurosci. Res."},{"key":"10.1016\/j.ymthe.2022.09.017_bib51","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1096\/fj.05-3826fje","article-title":"Enzyme replacement therapy results in substantial improvements in early clinical phenotype in a mouse model of globoid cell leukodystrophy","volume":"19","author":"Lee","year":"2005","journal-title":"FASEB J."},{"key":"10.1016\/j.ymthe.2022.09.017_bib52","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1089\/hum.2017.151","article-title":"AAVrh10 gene therapy ameliorates central and peripheral nervous system disease in canine globoid cell leukodystrophy (krabbe disease)","volume":"29","author":"Bradbury","year":"2018","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2022.09.017_bib53","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.ymthe.2018.01.009","article-title":"Long-term improvement of neurological signs and metabolic dysfunction in a mouse model of krabbe's disease after global gene therapy","volume":"26","author":"Marshall","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2022.09.017_bib54","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1203\/00006450-200201000-00009","article-title":"Substrate-reduction therapy enhances the benefits of bone marrow transplantation in young mice with globoid cell leukodystrophy","volume":"51","author":"Biswas","year":"2002","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.ymthe.2022.09.017_bib55","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1093\/hmg\/ddq099","article-title":"Widespread enzymatic correction of CNS tissues by a single intracerebral injection of therapeutic lentiviral vector in leukodystrophy mouse models","volume":"19","author":"Lattanzi","year":"2010","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymthe.2022.09.017_bib56","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1002\/jnr.23882","article-title":"Intrathecal administration of AAV\/GALC vectors in 10-11-day-old twitcher mice improves survival and is enhanced by bone marrow transplant","volume":"94","author":"Karumuthil-Melethil","year":"2016","journal-title":"J.\u00a0Neurosci. Res."},{"key":"10.1016\/j.ymthe.2022.09.017_bib57","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.ymthe.2020.12.031","article-title":"Enhanced efficacy and increased long-term toxicity of CNS-directed, AAV-based combination therapy for krabbe disease","volume":"29","author":"Li","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2022.09.017_bib58","doi-asserted-by":"crossref","first-page":"4906","DOI":"10.1172\/JCI133953","article-title":"Krabbe disease successfully treated via monotherapy of intrathecal gene therapy","volume":"130","author":"Bradbury","year":"2020","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2022.09.017_bib59","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1046\/j.1471-4159.1996.66031118.x","article-title":"Molecular cloning and expression of cDNA for murine galactocerebrosidase and mutation analysis of the twitcher mouse, a model of Krabbe's disease","volume":"66","author":"Sakai","year":"1996","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.ymthe.2022.09.017_bib60","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.nbd.2006.03.005","article-title":"Suppression of galactosylceramidase (GALC) expression in the twitcher mouse model of globoid cell leukodystrophy (GLD) is caused by nonsense-mediated mRNA decay (NMD)","volume":"23","author":"Lee","year":"2006","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.ymthe.2022.09.017_bib61","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1093\/brain\/103.3.695","article-title":"Hereditary leucodystrophy in the mouse: the new mutant twitcher","volume":"103","author":"Duchen","year":"1980","journal-title":"Brain."},{"key":"10.1016\/j.ymthe.2022.09.017_bib62","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1742-2094-2-10","article-title":"Anti-inflammatory therapy by ibudilast, a phosphodiesterase inhibitor, in demyelination of twitcher, a genetic demyelination model","volume":"2","author":"Kagitani-Shimono","year":"2005","journal-title":"J.\u00a0Neuroinflammation"},{"key":"10.1016\/j.ymthe.2022.09.017_bib63","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0165-5728(96)00166-X","article-title":"IL-6 and TNFalpha expression in brains of twitcher, quaking and normal mice","volume":"73","author":"LeVine","year":"1997","journal-title":"J.\u00a0Neuroimmunol."},{"key":"10.1016\/j.ymthe.2022.09.017_bib64","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/0006-8993(93)90692-G","article-title":"Proliferation of microglia\/macrophages in the demyelinating CNS and PNS of twitcher mouse","volume":"602","author":"Ohno","year":"1993","journal-title":"Brain Res."},{"key":"10.1016\/j.ymthe.2022.09.017_bib65","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1006\/mgme.2001.3194","article-title":"Generation of a mouse with low galactocerebrosidase activity by gene targeting: a new model of globoid cell leukodystrophy (Krabbe disease)","volume":"73","author":"Luzi","year":"2001","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymthe.2022.09.017_bib66","doi-asserted-by":"crossref","first-page":"5356","DOI":"10.1038\/s41467-020-19179-w","article-title":"Brainstem development requires galactosylceramidase and is critical for pathogenesis in a model of Krabbe disease","volume":"11","author":"Weinstock","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2022.09.017_bib67","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1006\/dbio.2002.0597","article-title":"Efficient recombination in diverse tissues by a tamoxifen-inducible form of Cre: a tool for temporally regulated gene activation\/inactivation in the mouse","volume":"244","author":"Hayashi","year":"2002","journal-title":"Dev. Biol."},{"key":"10.1016\/j.ymthe.2022.09.017_bib68","doi-asserted-by":"crossref","first-page":"9032","DOI":"10.1073\/pnas.1917675117","article-title":"Cell-autonomous expression of the acid hydrolase galactocerebrosidase","volume":"117","author":"Mikulka","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2022.09.017_bib69","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1007\/BF00687362","article-title":"The peripheral neuropathy of canine globoid-cell leukodystrophy (krabbe-type)","volume":"16","author":"Kurtz","year":"1970","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.ymthe.2022.09.017_bib70","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1097\/00005072-197701000-00009","article-title":"Quantitative evaluation of spinal cord lesions in canine globoid leukodystrophy","volume":"36","author":"Fletcher","year":"1977","journal-title":"J.\u00a0Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.ymthe.2022.09.017_bib71","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1093\/jhered\/90.1.138","article-title":"Globoid cell leukodystrophy in cairn and West Highland white terriers","volume":"90","author":"Wenger","year":"1999","journal-title":"J.\u00a0Hered."},{"key":"10.1016\/j.ymthe.2022.09.017_bib72","first-page":"375","article-title":"Animal model: globoid cell leukodystrophy in the dog","volume":"66","author":"Fletcher","year":"1972","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.ymthe.2022.09.017_bib73","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1002\/jnr.23838","article-title":"Clinical, electrophysiological, and biochemical markers of peripheral and central nervous system disease in canine globoid cell leukodystrophy (Krabbe's disease)","volume":"94","author":"Bradbury","year":"2016","journal-title":"J.\u00a0Neurosci. Res."},{"key":"10.1016\/j.ymthe.2022.09.017_bib74","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1177\/1971400916665378","article-title":"Diffusion tensor imaging analysis of the brain in the canine model of Krabbe disease","volume":"29","author":"Bradbury","year":"2016","journal-title":"Neuroradiol. J."},{"key":"10.1016\/j.ymthe.2022.09.017_bib75","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1212\/WNL.0000000000004418","article-title":"Developmental outcomes of cord blood transplantation for Krabbe disease: a 15-year study","volume":"89","author":"Wright","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.ymthe.2022.09.017_bib76","doi-asserted-by":"crossref","first-page":"4259","DOI":"10.1073\/pnas.84.12.4259","article-title":"Hematopoietic cell transplantation in murine globoid cell leukodystrophy (the twitcher mouse): effects on levels of galactosylceramidase, psychosine, and galactocerebrosides","volume":"84","author":"Ichioka","year":"1987","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2022.09.017_bib77","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1172\/JCI113521","article-title":"Effect of bone marrow transplantation on enzyme levels and clinical course in the neurologically affected twitcher mouse","volume":"81","author":"Hoogerbrugge","year":"1988","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2022.09.017_bib78","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ymgme.2012.05.021","article-title":"Bone marrow transplantation increases efficacy of central nervous system-directed enzyme replacement therapy in the murine model of globoid cell leukodystrophy","volume":"107","author":"Qin","year":"2012","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymthe.2022.09.017_bib79","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJM199804163381605","article-title":"Hematopoietic stem-cell transplantation in globoid-cell leukodystrophy","volume":"338","author":"Krivit","year":"1998","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2022.09.017_bib80","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1186\/s13023-020-01489-3","article-title":"Natural history of Krabbe disease - a nationwide study in Germany using clinical and MRI data","volume":"15","author":"Krieg","year":"2020","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymthe.2022.09.017_bib81","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1038\/s41436-019-0480-7","article-title":"Clinical characteristics of 248 patients with Krabbe disease: quantitative natural history modeling based on published cases","volume":"21","author":"Komatsuzaki","year":"2019","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymthe.2022.09.017_bib82","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1056\/NEJMoa042604","article-title":"Transplantation of umbilical-cord blood in babies with infantile Krabbe's disease","volume":"352","author":"Escolar","year":"2005","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2022.09.017_bib83","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s13023-015-0313-y","article-title":"Long-term outcomes after allogeneic hematopoietic stem cell transplantation for metachromatic leukodystrophy: the largest single-institution cohort report","volume":"10","author":"Boucher","year":"2015","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymthe.2022.09.017_bib84","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1182\/bloodadvances.2020001708","article-title":"Hurdles in treating Hurler disease: potential routes to achieve a \"real\" cure","volume":"4","author":"van den Broek","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.ymthe.2022.09.017_bib85","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/j.bbmt.2015.02.011","article-title":"Hematopoietic cell transplantation for mucopolysaccharidosis patients is safe and effective: results after implementation of international guidelines","volume":"21","author":"Aldenhoven","year":"2015","journal-title":"Biol. Blood Marrow Transpl."},{"key":"10.1016\/j.ymthe.2022.09.017_bib86","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13023-018-0766-x","article-title":"Consensus guidelines for newborn screening, diagnosis and treatment of infantile Krabbe disease","volume":"13","author":"Kwon","year":"2018","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymthe.2022.09.017_bib87","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1182\/bloodadvances.2021006094","article-title":"Benefits of newborn screening and hematopoietic cell transplant in infantile Krabbe disease","volume":"6","author":"Page","year":"2022","journal-title":"Blood Adv."},{"key":"10.1016\/j.ymthe.2022.09.017_bib88","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ymgme.2009.01.005","article-title":"Significant correction of pathology in brains of twitcher mice following injection of genetically modified mouse neural progenitor cells","volume":"97","author":"Strazza","year":"2009","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymthe.2022.09.017_bib89","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1002\/stem.701","article-title":"Neural stem cell gene therapy ameliorates pathology and function in a mouse model of globoid cell leukodystrophy","volume":"29","author":"Neri","year":"2011","journal-title":"Stem Cells"},{"key":"10.1016\/j.ymthe.2022.09.017_bib90","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/stem.555","article-title":"Mesenchymal lineage stem cells have pronounced anti-inflammatory effects in the twitcher mouse model of Krabbe's disease","volume":"29","author":"Ripoll","year":"2011","journal-title":"Stem Cells"},{"key":"10.1016\/j.ymthe.2022.09.017_bib91","doi-asserted-by":"crossref","first-page":"14486","DOI":"10.1038\/s41598-021-93601-1","article-title":"Substrate reduction therapy for Krabbe disease and metachromatic leukodystrophy using a novel ceramide galactosyltransferase inhibitor","volume":"11","author":"Babcock","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymthe.2022.09.017_bib92","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.brainres.2009.09.017","article-title":"Effects of treatments on inflammatory and apoptotic markers in the CNS of mice with globoid cell leukodystrophy","volume":"1300","author":"Luzi","year":"2009","journal-title":"Brain Res."},{"key":"10.1016\/j.ymthe.2022.09.017_bib93","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.ymgme.2014.05.009","article-title":"Pharmacological chaperones increase residual beta-galactocerebrosidase activity in fibroblasts from Krabbe patients","volume":"112","author":"Berardi","year":"2014","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymthe.2022.09.017_bib94","doi-asserted-by":"crossref","first-page":"5489","DOI":"10.1523\/JNEUROSCI.6383-09.2010","article-title":"Molecular characterization of mutations that cause globoid cell leukodystrophy and pharmacological rescue using small molecule chemical chaperones","volume":"30","author":"Lee","year":"2010","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.ymthe.2022.09.017_bib95","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/jhg.2015.61","article-title":"Chaperone therapy for Krabbe disease: potential for late-onset GALC mutations","volume":"60","author":"Hossain","year":"2015","journal-title":"J.\u00a0Hum. Genet."},{"key":"10.1016\/j.ymthe.2022.09.017_bib96","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1039\/C5SC00754B","article-title":"Azasugar inhibitors as pharmacological chaperones for Krabbe disease","volume":"6","author":"Hill","year":"2015","journal-title":"Chem. Sci."},{"key":"10.1016\/j.ymthe.2022.09.017_bib97","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1038\/sj.gt.3301495","article-title":"Intraventricular administration of recombinant adenovirus to neonatal twitcher mouse leads to clinicopathological improvements","volume":"8","author":"Shen","year":"2001","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2022.09.017_bib98","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.ymthe.2005.04.019","article-title":"AAV2\/5 vector expressing galactocerebrosidase ameliorates CNS disease in the murine model of globoid-cell leukodystrophy more efficiently than AAV2","volume":"12","author":"Lin","year":"2005","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2022.09.017_bib99","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1038\/mt.2012.153","article-title":"Extended normal life after AAVrh10-mediated gene therapy in the mouse model of Krabbe disease","volume":"20","author":"Rafi","year":"2012","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2022.09.017_bib100","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/sj.mt.6300026","article-title":"Central nervous system-directed AAV2\/5-mediated gene therapy synergizes with bone marrow transplantation in the murine model of globoid-cell leukodystrophy","volume":"15","author":"Lin","year":"2007","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2022.09.017_bib101","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.ymthe.2004.12.020","article-title":"AAV-mediated expression of galactocerebrosidase in brain results in attenuated symptoms and extended life span in murine models of globoid cell leukodystrophy","volume":"11","author":"Rafi","year":"2005","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2022.09.017_bib102","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1002\/jgm.924","article-title":"Design and optimization of lentiviral vectors for transfer of GALC expression in Twitcher brain","volume":"8","author":"Dolcetta","year":"2006","journal-title":"J.\u00a0Gene Med."},{"key":"10.1016\/j.ymthe.2022.09.017_bib103","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1096\/fj.06-6169com","article-title":"Single-dose intracerebroventricular administration of galactocerebrosidase improves survival in a mouse model of globoid cell leukodystrophy","volume":"21","author":"Lee","year":"2007","journal-title":"FASEB J."},{"key":"10.1016\/j.ymthe.2022.09.017_bib104","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.ymgme.2011.05.005","article-title":"CNS-targeted AAV5 gene transfer results in global dispersal of vector and prevention of morphological and function deterioration in CNS of globoid cell leukodystrophy mouse model","volume":"103","author":"Lin","year":"2011","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymthe.2022.09.017_bib105","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.bbr.2011.07.051","article-title":"Effect of intrastriatal mesenchymal stromal cell injection on progression of a murine model of Krabbe disease","volume":"225","author":"Wicks","year":"2011","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.ymthe.2022.09.017_bib106","doi-asserted-by":"crossref","first-page":"9945","DOI":"10.1523\/JNEUROSCI.1802-11.2011","article-title":"Bone marrow transplantation augments the effect of brain- and spinal cord-directed adeno-associated virus 2\/5 gene therapy by altering inflammation in the murine model of globoid-cell leukodystrophy","volume":"31","author":"Reddy","year":"2011","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.ymthe.2022.09.017_bib107","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1089\/hum.2021.245","article-title":"Efficacy and safety of a krabbe disease gene therapy","volume":"33","author":"Hordeaux","year":"2022","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2022.09.017_bib108","doi-asserted-by":"crossref","first-page":"135","DOI":"10.34172\/bi.2021.21","article-title":"Can early treatment of twitcher mice with high dose AAVrh10-GALC eliminate the need for BMT?","volume":"11","author":"Rafi","year":"2021","journal-title":"Bioimpacts."},{"key":"10.1016\/j.ymthe.2022.09.017_bib109","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1002\/jnr.22006","article-title":"Combined hematopoietic and lentiviral gene-transfer therapies in newborn Twitcher mice reveal contemporaneous neurodegeneration and demyelination in Krabbe disease","volume":"87","author":"Galbiati","year":"2009","journal-title":"J.\u00a0Neurosci. Res."},{"key":"10.1016\/j.ymthe.2022.09.017_bib110","doi-asserted-by":"crossref","first-page":"6495","DOI":"10.1523\/JNEUROSCI.4199-14.2015","article-title":"Mechanism-based combination treatment dramatically increases therapeutic efficacy in murine globoid cell leukodystrophy","volume":"35","author":"Hawkins-Salsbury","year":"2015","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.ymthe.2022.09.017_bib111","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1038\/mt.2015.145","article-title":"Long-term improvements in lifespan and pathology in CNS and PNS after BMT plus one intravenous injection of AAVrh10-GALC in twitcher mice","volume":"23","author":"Rafi","year":"2015","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2022.09.017_bib112","doi-asserted-by":"crossref","first-page":"3372","DOI":"10.1093\/hmg\/ddv086","article-title":"Combined gene\/cell therapies provide long-term and pervasive rescue of multiple pathological symptoms in a murine model of globoid cell leukodystrophy","volume":"24","author":"Ricca","year":"2015","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymthe.2022.09.017_bib113","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1126\/science.162.3853.570","article-title":"Hurler and Hunter syndromes: mutual correction of the defect in cultured fibroblasts","volume":"162","author":"Fratantoni","year":"1968","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2022.09.017_bib114","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/305713a0","article-title":"Enzyme replacement in grafted nerve of twitcher mouse","volume":"305","author":"Scaravilli","year":"1983","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2022.09.017_bib115","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1006\/bmme.1996.0042","article-title":"Retroviral vector-mediated transfer of the galactocerebrosidase (GALC) cDNA leads to overexpression and transfer of GALC activity to neighboring cells","volume":"58","author":"Rafi","year":"1996","journal-title":"Biochem. Mol. Med."},{"key":"10.1016\/j.ymthe.2022.09.017_bib116","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1006\/nbdi.2001.0407","article-title":"Retrovirus-mediated gene transfer and galactocerebrosidase uptake into twitcher glial cells results in appropriate localization and phenotype correction","volume":"8","author":"Luddi","year":"2001","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.ymthe.2022.09.017_bib117","doi-asserted-by":"crossref","first-page":"18670","DOI":"10.1073\/pnas.0506473102","article-title":"Galactocerebrosidase-deficient oligodendrocytes maintain stable central myelin by exogenous replacement of the missing enzyme in mice","volume":"102","author":"Kondo","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2022.09.017_bib118","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/S0021-9258(19)68020-8","article-title":"The enzymatic synthesis of sphingosine","volume":"233","author":"Brady","year":"1958","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ymthe.2022.09.017_bib119","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1128\/AAC.26.2.211","article-title":"Comparative inhibition of bacterial and microsomal 3-ketodihydrosphingosine synthetases by L-cycloserine and other inhibitors","volume":"26","author":"Sundaram","year":"1984","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ymthe.2022.09.017_bib120","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s11745-998-0226-6","article-title":"Cycloserine-induced decrease of cerebroside in myelin","volume":"33","author":"Miller","year":"1998","journal-title":"Lipids"},{"key":"10.1016\/j.ymthe.2022.09.017_bib121","doi-asserted-by":"crossref","first-page":"3634","DOI":"10.1021\/acs.jmedchem.9b02004","article-title":"Lead optimization of benzoxazolone carboxamides as orally bioavailable and CNS penetrant acid ceramidase inhibitors","volume":"63","author":"Di Martino","year":"2020","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ymthe.2022.09.017_bib122","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1038\/mt.2016.53","article-title":"CNS-Accessible inhibitor of glucosylceramide synthase for substrate reduction therapy of neuronopathic gaucher disease","volume":"24","author":"Marshall","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2022.09.017_bib123","doi-asserted-by":"crossref","first-page":"E178","DOI":"10.3390\/ijms18010178","article-title":"Less is more: substrate reduction therapy for lysosomal storage disorders","volume":"18","author":"Coutinho","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymthe.2022.09.017_bib124","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/j.1651-2227.2008.00656.x","article-title":"Substrate reduction therapy","volume":"97","author":"Platt","year":"2008","journal-title":"Acta Paediatr."},{"key":"10.1016\/j.ymthe.2022.09.017_bib125","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1080\/17446651.2018.1445524","article-title":"Recent advances in the diagnosis and management of Gaucher disease","volume":"13","author":"Gary","year":"2018","journal-title":"Expert Rev. Endocrinol. Metab."},{"key":"10.1016\/j.ymthe.2022.09.017_bib126","doi-asserted-by":"crossref","first-page":"E441","DOI":"10.3390\/ijms18020441","article-title":"A review of gaucher disease pathophysiology, clinical presentation and treatments","volume":"18","author":"Stirnemann","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymthe.2022.09.017_bib127","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1023\/B:BOLI.0000045756.54006.17","article-title":"Sustained therapeutic effects of oral miglustat (Zavesca, N-butyldeoxynojirimycin, OGT 918) in type I Gaucher disease","volume":"27","author":"Elstein","year":"2004","journal-title":"J.\u00a0Inherit. Metab. Dis."},{"key":"10.1016\/j.ymthe.2022.09.017_bib128","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.clinthera.2005.08.004","article-title":"An open-label, noncomparative study of miglustat in type I Gaucher disease: efficacy and tolerability over 24\u00a0months of treatment","volume":"27","author":"Pastores","year":"2005","journal-title":"Clin. Ther."},{"key":"10.1016\/j.ymthe.2022.09.017_bib129","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/S0140-6736(00)02161-9","article-title":"Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis","volume":"355","author":"Cox","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2022.09.017_bib130","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/S1474-4422(07)70194-1","article-title":"Miglustat for treatment of Niemann-Pick C disease: a randomised controlled study","volume":"6","author":"Patterson","year":"2007","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ymthe.2022.09.017_bib131","doi-asserted-by":"crossref","first-page":"e12836","DOI":"10.15252\/emmm.202012836","article-title":"The rapidly evolving view of lysosomal storage diseases","volume":"13","author":"Parenti","year":"2021","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.ymthe.2022.09.017_bib132","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1002\/cpdd.865","article-title":"Pharmacokinetics, pharmacodynamics, safety, and tolerability of oral Venglustat in healthy volunteers","volume":"10","author":"Peterschmitt","year":"2021","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"10.1016\/j.ymthe.2022.09.017_bib133","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.ekir.2019.11.013","article-title":"Current and investigational therapeutics for Fabry disease","volume":"5","author":"Felis","year":"2020","journal-title":"Kidney Int. Rep."},{"key":"10.1016\/j.ymthe.2022.09.017_bib134","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1007\/s00431-001-0859-7","article-title":"Glucocerebrosidase level in the cerebrospinal fluid during enzyme replacement therapy--unsuccessful treatment of the neurological abnormality in type 2 Gaucher disease","volume":"162","author":"Migita","year":"2003","journal-title":"Eur. J. Pediatr."},{"key":"10.1016\/j.ymthe.2022.09.017_bib135","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.omtm.2020.05.026","article-title":"Enzyme replacement therapy can reverse pathogenic cascade in Pompe disease","volume":"18","author":"Meena","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2022.09.017_bib136","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1056\/NEJMoa1712649","article-title":"Study of intraventricular cerliponase alfa for CLN2 disease","volume":"378","author":"Schulz","year":"2018","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2022.09.017_bib137","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1177\/0883073821989154","article-title":"Development of the \"hamburg best practice guidelines for ICV-enzyme replacement therapy (ERT) in CLN2 disease\" based on 6 Years treatment experience in 48 patients","volume":"36","author":"Schwering","year":"2021","journal-title":"J.\u00a0Child Neurol."},{"key":"10.1016\/j.ymthe.2022.09.017_bib138","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1542\/peds.2007-2144","article-title":"Eight-year clinical outcomes of long-term enzyme replacement therapy for 884 children with Gaucher disease type 1","volume":"122","author":"Andersson","year":"2008","journal-title":"Pediatrics"},{"key":"10.1016\/j.ymthe.2022.09.017_bib139","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.ymgme.2020.07.002","article-title":"Safety of intrathecal delivery of recombinant human arylsulfatase A in children with metachromatic leukodystrophy: results from a phase 1\/2 clinical trial","volume":"131","author":"\u00ed Dali","year":"2020","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymthe.2022.09.017_bib140","doi-asserted-by":"crossref","first-page":"E400","DOI":"10.3390\/ijms21020400","article-title":"Novel enzyme replacement therapies for neuropathic mucopolysaccharidoses","volume":"21","author":"Sato","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymthe.2022.09.017_bib141","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1111\/j.1471-4159.1985.tb07167.x","article-title":"Human blood-brain barrier insulin receptor","volume":"44","author":"Pardridge","year":"1985","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.ymthe.2022.09.017_bib142","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1172\/JCI119125","article-title":"Human blood-brain barrier leptin receptor. Binding and endocytosis in isolated human brain microvessels","volume":"99","author":"Golden","year":"1997","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2022.09.017_bib143","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/jnr.490180206","article-title":"Receptor-mediated transcytosis of transferrin across the blood-brain barrier","volume":"18","author":"Fishman","year":"1987","journal-title":"J.\u00a0Neurosci. Res."},{"key":"10.1016\/j.ymthe.2022.09.017_bib144","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/312162a0","article-title":"Transferrin receptor on endothelium of brain capillaries","volume":"312","author":"Jefferies","year":"1984","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2022.09.017_bib145","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/0026-0495(87)90099-0","article-title":"Human blood-brain barrier transferrin receptor","volume":"36","author":"Pardridge","year":"1987","journal-title":"Metabolism"},{"key":"10.1016\/j.ymthe.2022.09.017_bib146","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/j.ymthe.2018.02.032","article-title":"A blood-brain-barrier-penetrating anti-human transferrin receptor antibody fusion protein for neuronopathic mucopolysaccharidosis II","volume":"26","author":"Sonoda","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2022.09.017_bib147","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.ymgme.2014.09.004","article-title":"Nonclinical evaluation of CNS-administered TPP1 enzyme replacement in canine CLN2 neuronal ceroid lipofuscinosis","volume":"114","author":"Vuillemenot","year":"2015","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymthe.2022.09.017_bib148","doi-asserted-by":"crossref","first-page":"614","DOI":"10.12688\/f1000research.54556.1","article-title":"Cerebrospinal fluid neurofilament light chain levels in CLN2 disease patients treated with enzyme replacement therapy normalise after two years on treatment","volume":"10","author":"Iwan","year":"2021","journal-title":"F1000Res."},{"key":"10.1016\/j.ymthe.2022.09.017_bib149","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.ymthe.2004.05.024","article-title":"Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system","volume":"10","author":"Burger","year":"2004","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2022.09.017_bib150","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.ymthe.2005.11.015","article-title":"Transduction characteristics of adeno-associated virus vectors expressing cap serotypes 7, 8, 9, and Rh10 in the mouse brain","volume":"13","author":"Cearley","year":"2006","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2022.09.017_bib151","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1089\/hum.2006.178","article-title":"Comparative analysis of adeno-associated viral vector serotypes 1, 2, 5, 7, and 8 in mouse brain","volume":"18","author":"Taymans","year":"2007","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2022.09.017_bib152","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1038\/mt.2008.166","article-title":"Expanded repertoire of AAV vector serotypes mediate unique patterns of transduction in mouse brain","volume":"16","author":"Cearley","year":"2008","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2022.09.017_bib153","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/sj.mt.6300331","article-title":"AAV8, 9, Rh10, Rh43 vector gene transfer in the rat brain: effects of serotype, promoter and purification method","volume":"16","author":"Klein","year":"2008","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2022.09.017_bib154","doi-asserted-by":"crossref","first-page":"661857","DOI":"10.3389\/fncel.2021.661857","article-title":"Emerging concepts in vector development for glial gene therapy: implications for leukodystrophies","volume":"15","author":"von Jonquieres","year":"2021","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.ymthe.2022.09.017_bib155","doi-asserted-by":"crossref","first-page":"7034","DOI":"10.1128\/JVI.77.12.7034-7040.2003","volume":"77","author":"Passini","year":"2003","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ymthe.2022.09.017_bib156","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1089\/hum.1998.9.8-1181","article-title":"Selective and rapid uptake of adeno-associated virus type 2 in brain","volume":"9","author":"Bartlett","year":"1998","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2022.09.017_bib157","doi-asserted-by":"crossref","first-page":"e65646","DOI":"10.1371\/journal.pone.0065646","article-title":"Glial promoter selectivity following AAV-delivery to the immature brain","volume":"8","author":"von Jonquieres","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ymthe.2022.09.017_bib158","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.neures.2014.09.002","article-title":"Comparative analyses of adeno-associated viral vector serotypes 1, 2, 5, 8 and 9 in marmoset, mouse and macaque cerebral cortex","volume":"93","author":"Watakabe","year":"2015","journal-title":"Neurosci. Res."},{"key":"10.1016\/j.ymthe.2022.09.017_bib159","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/s10038-018-0537-5","article-title":"Gene therapy for lysosomal storage diseases and peroxisomal diseases","volume":"64","author":"Ohashi","year":"2019","journal-title":"J.\u00a0Hum. Genet."},{"key":"10.1016\/j.ymthe.2022.09.017_bib160","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/sj.mt.6300004","article-title":"Complete correction of enzymatic deficiency and neurochemistry in the GM1-gangliosidosis mouse brain by neonatal adeno-associated virus-mediated gene delivery","volume":"15","author":"Broekman","year":"2007","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2022.09.017_bib161","doi-asserted-by":"crossref","first-page":"4353","DOI":"10.1093\/hmg\/ddv168","article-title":"Systemic AAV9 gene transfer in adult GM1 gangliosidosis mice reduces lysosomal storage in CNS and extends lifespan","volume":"24","author":"Weismann","year":"2015","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymthe.2022.09.017_bib162","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1093\/brain\/awab309","article-title":"Intravenous delivery of adeno-associated viral gene therapy in feline GM1 gangliosidosis","volume":"145","author":"Gross","year":"2022","journal-title":"Brain."},{"key":"10.1016\/j.ymthe.2022.09.017_bib163","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1172\/JCI119322","article-title":"Murine mucopolysaccharidosis type VII: long term therapeutic effects of enzyme replacement and enzyme replacement followed by bone marrow transplantation","volume":"99","author":"Sands","year":"1997","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2022.09.017_bib164","doi-asserted-by":"crossref","first-page":"R54","DOI":"10.1093\/hmg\/ddr112","article-title":"Combination therapies for lysosomal storage disease: is the whole greater than the sum of its parts?","volume":"20","author":"Hawkins-Salsbury","year":"2011","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymthe.2022.09.017_bib165","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/ana.23545","article-title":"Synergistic effects of central nervous system-directed gene therapy and bone marrow transplantation in the murine model of infantile neuronal ceroid lipofuscinosis","volume":"71","author":"Macauley","year":"2012","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ymthe.2022.09.017_bib166","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1182\/blood.V97.1.327","article-title":"Enhanced survival in Sandhoff disease mice receiving a combination of substrate deprivation therapy and bone marrow transplantation","volume":"97","author":"Jeyakumar","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2022.09.017_bib167","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s10545-010-9072-z","article-title":"Improved management of lysosomal glucosylceramide levels in a mouse model of type 1 Gaucher disease using enzyme and substrate reduction therapy","volume":"33","author":"Marshall","year":"2010","journal-title":"J.\u00a0Inherit. Metab. Dis."},{"key":"10.1016\/j.ymthe.2022.09.017_bib168","doi-asserted-by":"crossref","first-page":"B379","DOI":"10.1093\/gerona\/57.11.B379","article-title":"Survival characteristics and age-adjusted disease incidences in C57BL\/6 mice fed a commonly used cereal-based diet modulated by dietary restriction","volume":"57","author":"Turturro","year":"2002","journal-title":"J.\u00a0Gerontol. A. Biol. Sci. Med. Sci."},{"key":"10.1016\/j.ymthe.2022.09.017_bib169","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1016\/j.ymthe.2021.01.026","article-title":"Waning efficacy in a long-term AAV-mediated gene therapy study in the murine model of Krabbe disease","volume":"29","author":"Heller","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2022.09.017_bib170","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.1128\/jvi.70.5.3235-3241.1996","article-title":"In\u00a0vivo model of adeno-associated virus vector persistence and rescue","volume":"70","author":"Afione","year":"1996","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ymthe.2022.09.017_bib171","doi-asserted-by":"crossref","first-page":"8568","DOI":"10.1128\/JVI.72.11.8568-8577.1998","article-title":"Circular intermediates of recombinant adeno-associated virus have defined structural characteristics responsible for long-term episomal persistence in muscle tissue","volume":"72","author":"Duan","year":"1998","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ymthe.2022.09.017_bib172","doi-asserted-by":"crossref","first-page":"6969","DOI":"10.1128\/JVI.75.15.6969-6976.2001","article-title":"Extrachromosomal recombinant adeno-associated virus vector genomes are primarily responsible for stable liver transduction in\u00a0vivo","volume":"75","author":"Nakai","year":"2001","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ymthe.2022.09.017_bib173","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1146\/annurev.genet.37.110801.143717","article-title":"Integration of adeno-associated virus (AAV) and recombinant AAV vectors","volume":"38","author":"McCarty","year":"2004","journal-title":"Annu. Rev. Genet."},{"key":"10.1016\/j.ymthe.2022.09.017_bib174","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1093\/hmg\/4.10.1865","article-title":"Molecular defects in Krabbe disease","volume":"4","author":"Tatsumi","year":"1995","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymthe.2022.09.017_bib175","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/(SICI)1098-1136(199802)22:2<161::AID-GLIA7>3.0.CO;2-A","article-title":"Response of the oligodendrocyte progenitor cell population (defined by NG2 labelling) to demyelination of the adult spinal cord","volume":"22","author":"Keirstead","year":"1998","journal-title":"Glia"},{"key":"10.1016\/j.ymthe.2022.09.017_bib176","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0166-2236(00)01691-X","article-title":"The oligodendrocyte precursor cell in health and disease","volume":"24","author":"Levine","year":"2001","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.ymthe.2022.09.017_bib177","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0079-6123(01)32073-3","article-title":"The response of adult oligodendrocyte progenitors to demyelination in EAE","volume":"132","author":"Reynolds","year":"2001","journal-title":"Prog. Brain Res."},{"key":"10.1016\/j.ymthe.2022.09.017_bib178","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.expneurol.2014.04.027","article-title":"Oligodendrocyte progenitors: adult stem cells of the central nervous system?","volume":"260","author":"Crawford","year":"2014","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.ymthe.2022.09.017_bib179","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1038\/sj.gt.3302033","article-title":"Attenuation of ganglioside GM1 accumulation in the brain of GM1 gangliosidosis mice by neonatal intravenous gene transfer","volume":"10","author":"Takaura","year":"2003","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2022.09.017_bib180","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.omtm.2019.11.023","article-title":"7T MRI predicts amelioration of neurodegeneration in the brain after AAV gene therapy","volume":"17","author":"Gray-Edwards","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2022.09.017_bib181","doi-asserted-by":"crossref","first-page":"20513","DOI":"10.1038\/s41598-021-99979-2","article-title":"Treatment of adult metachromatic leukodystrophy model mice using intrathecal administration of type 9 AAV vector encoding arylsulfatase A","volume":"11","author":"Miyake","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymthe.2022.09.017_bib182","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.ymthe.2020.09.033","article-title":"AAV9 gene therapy increases lifespan and treats pathological and behavioral abnormalities in a mouse model of CLN8-batten disease","volume":"29","author":"Johnson","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2022.09.017_bib183","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.omtm.2021.10.007","article-title":"AAV-mediated gene therapy for galactosialidosis: a long-term safety and efficacy study","volume":"23","author":"Hu","year":"2021","journal-title":"Mol. Ther. Methods Clin. Dev."},{"issue":"Pt 2","key":"10.1016\/j.ymthe.2022.09.017_bib184","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1099\/vir.0.035113-0","article-title":"Examining the cross-reactivity and neutralization mechanisms of a panel of mAbs against adeno-associated virus serotypes 1 and 5","volume":"93","author":"Harbison","year":"2012","journal-title":"J.\u00a0Gen. Virol."},{"key":"10.1016\/j.ymthe.2022.09.017_bib185","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/gt.2014.103","article-title":"AAVrh.10 immunogenicity in mice and humans. Relevance of antibody cross-reactivity in human gene therapy","volume":"22","author":"Thwaite","year":"2015","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2022.09.017_bib186","doi-asserted-by":"crossref","first-page":"3994","DOI":"10.1128\/JVI.73.5.3994-4003.1999","article-title":"Gene therapy vectors based on adeno-associated virus type 1","volume":"73","author":"Xiao","year":"1999","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ymthe.2022.09.017_bib187","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1128\/JVI.74.3.1524-1532.2000","article-title":"Repeat transduction in the mouse lung by using adeno-associated virus vectors with different serotypes","volume":"74","author":"Halbert","year":"2000","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ymthe.2022.09.017_bib188","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1038\/sj.gt.3302766","article-title":"Long-term expression and repeated administration of AAV type 1, 2 and 5 vectors in skeletal muscle of immunocompetent adult mice","volume":"13","author":"Rivi\u00e8re","year":"2006","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2022.09.017_bib189","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1182\/blood-2006-03-010181","article-title":"Safe and efficient transduction of the liver after peripheral vein infusion of self-complementary AAV vector results in stable therapeutic expression of human FIX in nonhuman primates","volume":"109","author":"Nathwani","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2022.09.017_bib190","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1016\/j.ymthe.2017.05.003","article-title":"Successful repeated hepatic gene delivery in mice and non-human primates achieved by sequential administration of AAV5(ch) and AAV1","volume":"25","author":"Majowicz","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2022.09.017_bib191","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1089\/hum.2017.016","article-title":"Gene delivery of activated factor VII using alternative adeno-associated virus serotype improves hemostasis in hemophiliac mice with FVIII inhibitors and adeno-associated virus neutralizing antibodies","volume":"28","author":"Sun","year":"2017","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2022.09.017_bib192","doi-asserted-by":"crossref","first-page":"14033","DOI":"10.1038\/mtm.2014.33","article-title":"B-cell depletion is protective against anti-AAV capsid immune response: a human subject case study","volume":"1","author":"Corti","year":"2014","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2022.09.017_bib193","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1038\/mt.2011.108","article-title":"A 10 patient case report on the impact of plasmapheresis upon neutralizing factors against adeno-associated virus (AAV) types 1, 2, 6, and 8","volume":"19","author":"Monteilhet","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2022.09.017_bib194","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1089\/hum.2016.128","article-title":"Characterization of adeno-associated viral vector-mediated human factor VIII gene therapy in hemophilia A mice","volume":"28","author":"Greig","year":"2017","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2022.09.017_bib195","doi-asserted-by":"crossref","first-page":"E119","DOI":"10.3390\/brainsci10020119","article-title":"Management of neuroinflammatory responses to AAV-mediated gene therapies for neurodegenerative diseases","volume":"10","author":"Perez","year":"2020","journal-title":"Brain Sci."},{"key":"10.1016\/j.ymthe.2022.09.017_bib196","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1089\/hum.2020.167","article-title":"Adeno-associated virus-induced dorsal root ganglion pathology","volume":"31","author":"Hordeaux","year":"2020","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2022.09.017_bib197","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1126\/science.1142658","article-title":"AAV vector integration sites in mouse hepatocellular carcinoma","volume":"317","author":"Donsante","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2022.09.017_bib198","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.ymthe.2020.10.018","article-title":"Liver injury increases the incidence of HCC following AAV gene therapy in mice","volume":"29","author":"Dalwadi","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2022.09.017_bib199","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1073\/pnas.68.4.820","article-title":"Mutation and cancer: statistical study of retinoblastoma","volume":"68","author":"Knudson","year":"1971","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2022.09.017_bib200","doi-asserted-by":"crossref","first-page":"6684","DOI":"10.1038\/ncomms7684","article-title":"The genome-wide effects of ionizing radiation on mutation induction in the mammalian germline","volume":"6","author":"Adewoye","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2022.09.017_bib201","doi-asserted-by":"crossref","first-page":"44311","DOI":"10.1074\/jbc.M406920200","article-title":"Defects in cell growth regulation by C18:0-ceramide and longevity assurance gene 1 in human head and neck squamous cell carcinomas","volume":"279","author":"Koybasi","year":"2004","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ymthe.2022.09.017_bib202","first-page":"1530","article-title":"Endocannabinoid system and the expression of endogenous ceramides in human hepatocellular carcinoma","volume":"18","author":"Yang","year":"2019","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.ymthe.2022.09.017_bib203","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/gt.2016.62","article-title":"Characterization of a novel adeno-associated viral vector with preferential oligodendrocyte tropism","volume":"23","author":"Powell","year":"2016","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2022.09.017_bib204","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1002\/(SICI)1097-4547(19990215)55:4<504::AID-JNR10>3.0.CO;2-0","article-title":"Oligodendrocyte-specific gene expression in mouse brain: use of a myelin-forming cell type-specific promoter in an adeno-associated virus","volume":"55","author":"Chen","year":"1999","journal-title":"J.\u00a0Neurosci. Res."},{"key":"10.1016\/j.ymthe.2022.09.017_bib205","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.ymgme.2014.12.300","article-title":"Intravenous injection of AAVrh10-GALC after the neonatal period in twitcher mice results in significant expression in the central and peripheral nervous systems and improvement of clinical features","volume":"114","author":"Rafi","year":"2015","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymthe.2022.09.017_bib206","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00443-2021","article-title":"Nutritional assessment in idiopathic pulmonary fibrosis: a prospective multicentre study","volume":"8","author":"Faverio","year":"2022","journal-title":"ERJ Open Res."},{"key":"10.1016\/j.ymthe.2022.09.017_bib207","doi-asserted-by":"crossref","first-page":"576221","DOI":"10.3389\/fmed.2020.576221","article-title":"Metachromatic leukodystrophy: diagnosis, modeling, and treatment approaches","volume":"7","author":"Shaimardanova","year":"2020","journal-title":"Front. Med."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001622006062?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001622006062?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:05:34Z","timestamp":1761501934000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001622006062"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":207,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S1525001622006062"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2022.09.017","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2022.09.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s).","name":"copyright","label":"Copyright"}]}}